BrainStorm Cell Tx publishes NurOwn ALS Phase 2 randomized trial data in neurology

(LaVoieHealthScience) Results from Brainstorm Cell Therapeutic's NurOwn randomized Phase 2 clinical trial were published in Neurology. The study demonstrated a single transplantation of MSC-NTF cells (NurOwn®) in ALS clinical trial participants met the primary safety endpoint and demonstrated promising stabilization of ALS disease progression of up to 12-16 weeks in a pre-specified subgroup of ALS rapid progressors. Cerebrospinal fluid analysis confirmed the biological action of MSC-NTF cells o...